Literature DB >> 33078896

Humanization of Chicken-Derived scFv Using Yeast Surface Display and NGS Data Mining.

Adrian Elter1,2, Jan P Bogen1,3, Steffen C Hinz1,2, David Fiebig1,3, Arturo Macarrón Palacios1, Julius Grzeschik3, Björn Hock4, Harald Kolmar1,2.   

Abstract

Generation of high-affinity monoclonal antibodies by immunization of chickens is a valuable strategy, particularly for obtaining antibodies directed against epitopes that are conserved in mammals. A generic procedure is established for the humanization of chicken-derived antibodies. To this end, high-affinity binders of the epidermal growth factor receptor extracellular domain are isolated from immunized chickens using yeast surface display. Complementarity determining regions (CDRs) of two high-affinity binders are grafted onto a human acceptor framework. Simultaneously, Vernier zone residues, responsible for spatial CDR arrangement, are partially randomized. A yeast surface display library comprising ≈300 000 variants is screened for high-affinity binders in the scFv and Fab formats. Next-generation sequencing discloses humanized antibody variants with restored affinity and improved protein characteristics compared to the parental chicken antibodies. Furthermore, the sequencing data give new insights into the importance of antibody format, used during the humanization process. Starting from the antibody repertoire of immunized chickens, this work features an effective and fast high-throughput approach for the generation of multiple humanized antibodies with potential therapeutic relevance.
© 2020 The Authors. Biotechnology Journal published by Wiley-VCH GmbH.

Entities:  

Keywords:  chicken antibody; fluorescence-activated cell sorting; humanization; next-generation sequencing; yeast surface display

Mesh:

Substances:

Year:  2020        PMID: 33078896     DOI: 10.1002/biot.202000231

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  7 in total

1.  A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization.

Authors:  Julia Harwardt; Jan P Bogen; Stefania C Carrara; Michael Ulitzka; Julius Grzeschik; Björn Hock; Harald Kolmar
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

2.  Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity.

Authors:  Adrian Elter; Desislava Yanakieva; David Fiebig; Kerstin Hallstein; Stefan Becker; Ulrich Betz; Harald Kolmar
Journal:  Front Immunol       Date:  2021-08-03       Impact factor: 7.561

Review 3. 

Authors:  Adrian Elter; Jan P Bogen; Jan Habermann; Harald Kolmar
Journal:  Biospektrum (Heidelb)       Date:  2021-09-04

4.  Streamlining the Transition From Yeast Surface Display of Antibody Fragment Immune Libraries to the Production as IgG Format in Mammalian Cells.

Authors:  David Fiebig; Jan P Bogen; Stefania C Carrara; Lukas Deweid; Stefan Zielonka; Julius Grzeschik; Björn Hock; Harald Kolmar
Journal:  Front Bioeng Biotechnol       Date:  2022-05-10

5.  Expeditious Generation of Biparatopic Common Light Chain Antibodies via Chicken Immunization and Yeast Display Screening.

Authors:  Jan P Bogen; Stefania C Carrara; David Fiebig; Julius Grzeschik; Björn Hock; Harald Kolmar
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

6.  Milking the Cow: Cattle-Derived Chimeric Ultralong CDR-H3 Antibodies and Their Engineered CDR-H3-Only Knobbody Counterparts Targeting Epidermal Growth Factor Receptor Elicit Potent NK Cell-Mediated Cytotoxicity.

Authors:  Lukas Pekar; Daniel Klewinghaus; Paul Arras; Stefania C Carrara; Julia Harwardt; Simon Krah; Desislava Yanakieva; Lars Toleikis; Vaughn V Smider; Harald Kolmar; Stefan Zielonka
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 7.561

7.  Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture.

Authors:  Jan P Bogen; Stefania C Carrara; David Fiebig; Julius Grzeschik; Björn Hock; Harald Kolmar
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.